drugset / Trial / NCT06960213
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
Timeline
- Start
- 2025-08-28
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |